Form 8-K - Current report:
SEC Accession No. 0001171843-26-002960
Filing Date
2026-05-04
Accepted
2026-05-04 07:06:53
Documents
13
Period of Report
2026-05-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_050426.htm   iXBRL 8-K 16406
2 PRESS RELEASE exh_991.htm EX-99.1 9589
  Complete submission text file 0001171843-26-002960.txt   227285

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20250101.xsd EX-101.SCH 3402
4 XBRL DEFINITION FILE gnw-20250101_def.xml EX-101.DEF 26066
5 XBRL LABEL FILE gnw-20250101_lab.xml EX-101.LAB 35956
6 XBRL PRESENTATION FILE gnw-20250101_pre.xml EX-101.PRE 24702
16 EXTRACTED XBRL INSTANCE DOCUMENT f8k_050426_htm.xml XML 2827
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 26934590
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)